The evolving role of familial history for prostate cancer

References

• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–81.
   PubMed Web of Science ®Google Scholar
• Carter B, Bova G, Beaty Y, Steinberg G, Childs B, Isaacs W, . Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 1993;150:797–802.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma from the Family-Cancer Database. Cancer 2002;95:1346–53.
   PubMedGoogle Scholar
• Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J, Albanes D. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Cancer 2008;123:1154–9.
   PubMedGoogle Scholar
• Cerhan JR, Parker AS, Putnam SD, Chiu BC, Lynch CF, Cohen MB, . Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 1999;8:53–60.
   PubMed Web of Science ®Google Scholar
• Kalish LA, Scott McDougal W, McKinlay JB. Family history and the risk of prostate cancer. Urology 2000;56:803–6.
   PubMedGoogle Scholar
• Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age at diagnosis and age at death in familial prostate cancer. Oncologist 2009;14:1209–17.
   PubMedGoogle Scholar
• Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789–94.
   PubMed Web of Science ®Google Scholar
• Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Cancer 2003;107:797–803.
   PubMed Web of Science ®Google Scholar
• Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci 1992;89:3367–71.
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, . Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78–85.
   PubMed Web of Science ®Google Scholar
• Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: A study of World War II veteran twins. Prostate 1997;33:240–5.
   PubMed Web of Science ®Google Scholar
• Ahlbom A, Lichtenstein P, Malmstrom H, Feychting M, Hemminki K, Pedersen NL. Cancer in twins: Genetic and nongenetic familial risk factors. J Natl Cancer Inst 1997; 89:287–93.
   PubMed Web of Science ®Google Scholar
• Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152:1484–9.
   PubMedGoogle Scholar
• Damber L, Gronberg H, Damber JE. Familial prostate cancer and possible associated malignancies: Nation-wide register cohort study in Sweden. Int J Cancer 1998;78:293–7.
   PubMedGoogle Scholar
• Schuurman AG, Zeegers MP, Goldbohm RA, van den Brandt PA. A case-cohort study on prostate cancer risk in relation to family history of prostate cancer. Epidemiology 1999; 10:192–5.
   PubMedGoogle Scholar
• Hemminki K, Sundquist J, Bermejo JL. How common is familial cancer? Ann Oncol 2008;19:163–7.
   PubMed Web of Science ®Google Scholar
• Verhage BA, Baffoe-Bonnie AB, Baglietto L, Smith DS, Bailey-Wilson JE, Beaty TH, . Autosomal dominant inheritance of prostate cancer: A confirmatory study. Urology 2001;57:97–101.
   PubMedGoogle Scholar
• Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, . Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995;1:827–9.
   PubMed Web of Science ®Google Scholar
• MacInnis R, Antoniou AC, Eeles RA, Severi G, Guy M, McGuffog L, . Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet Epidemiol 2010;34:42–50.
   PubMedGoogle Scholar
• Pakkanen S. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum Genet 2007;121:257–67.
   PubMed Web of Science ®Google Scholar
• Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: Evidence of the complex nature of the disease. Hum Mol Genet 2001;10:2313–8.
   PubMedGoogle Scholar
• Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, . Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics Using Novel sumLINK and sumLOD analyses. Prostate 2010;70:735–44.
   PubMedGoogle Scholar
• Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13:R103–21.
   PubMed Web of Science ®Google Scholar
• Schaid DJ, Chang BL. Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13. Prostate 2005;63:276–90.
   PubMedGoogle Scholar
• Witte JS. Multiple prostate cancer risk variants on 8q24. Nat Genet 2007;39:579–80.
   PubMedGoogle Scholar
• Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, . Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39:638–44.
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, . Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39:977–83.
   PubMed Web of Science ®Google Scholar
• Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, . Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci 2006;103:14068–73.
   PubMed Web of Science ®Google Scholar
• Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, . Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645–9.
   PubMed Web of Science ®Google Scholar
• Eeles RA, Kote-Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK, . Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316–21.
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, . Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008;17:2052–61.
   PubMed Web of Science ®Google Scholar
• Edwards SM, Kote-Jarai Z, Meitz J, . Two percent of men with early-onset prostate cancer harbour germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1–12.
   PubMed Web of Science ®Google Scholar
• Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, . Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310–5.
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, . Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008;40:281–3.
   PubMed Web of Science ®Google Scholar
• Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, . Prostate cancer susceptibility genes: Lessons learned and challenges posed. Endocrine-Related Cancer 2003;10:225–59.
   PubMed Web of Science ®Google Scholar
• Van der Poel HG. Molecular markers in the diagnosis of prostate cancer. Crit Rev Onc Hematol 2007;61:104–39.
   PubMed Web of Science ®Google Scholar
• Lindstrom S, Wiklund F, Adami H-O, Augustsson Balter K, Adolfsson J, Gronberg H. Germ-line genetic variation in the key androgen-regulating genes Androgen Receptor, Cytochrome P450, and Steroid-5-alpha-Reductase type 2 is important for prostate cancer development. Cancer Res 2006; 66:11077–83.
   PubMed Web of Science ®Google Scholar
• Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, . Endogenous sex hormones and prostate cancer risk: A case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003;12:1410–6.
   PubMed Web of Science ®Google Scholar
• Shaneyfelt T, Husein R, Bubley G, Mantzoros C. Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000;18:847–53.
   PubMed Web of Science ®Google Scholar
• Perry AS, Foley R, Woodson K, Lawler M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocrine-Related Cancer 2006;13:357–77.
   PubMed Web of Science ®Google Scholar
• Phè V, Cussenot O, Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010;105:1364–70.
   PubMed Web of Science ®Google Scholar
• Dianat SS, Margreiter M, Eckersberger E, Finkelstein J, Kuehas F, Herwig R, . Gene polymorphisms and prostate cancer: The evidence. BJU Int 2009;104:1560–72.
   PubMedGoogle Scholar
• Agalliu I, Langeberg WJ, Lampe JW, Salinas CA, Stanford JL. Glutathione S-Transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. Prostate 2006;66:146–56.
   PubMed Web of Science ®Google Scholar
• Brand TC, Bermejo C, Canby-Hagino E, Troyer DA, Baillargeon J, Thompson IM, . Association of polymorphisms in TGFB1 and prostate cancer prognosis. J Urol 2007;179:754–8.
   PubMedGoogle Scholar
• Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, . Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: The hidden face of estrogens. J Clin Oncol 2007; 25:3596–602.
   PubMedGoogle Scholar
• Mononen N, Seppala EH, Duggal P, Autio V, Ikonen T, Ellonen P, . Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 2006;66:743–7.
   PubMed Web of Science ®Google Scholar
• Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A, . Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006;27:1842–8.
   PubMed Web of Science ®Google Scholar
• Loeb S, Helfand BT, Kan D, Isaacs WB, Catalona WJ. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? BJU Int 2009; 104:1200–3.
   PubMedGoogle Scholar
• Ritchey JD, Huang W-Y, Chokkalingam AP, Gao Y-T, Deng J, Levine P, . Genetic variants of DNA repair genes and prostate cancer: A population-based study. Cancer Epidemiol Biomarkers Prev 2005;14:1703–9.
   PubMed Web of Science ®Google Scholar
• Platz EA, Leitzmann MF, Michaud DS, Willett WC, Giovannucci E. Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 2003;63:8542–8.
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Roberts WW, Walsh PC, Platz EA. Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate 2003;55:140–6.
   PubMed Web of Science ®Google Scholar
• Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, . Obesity is negatively associated with prostate-specific antigen in U.S. Men, 2001–2004. Cancer Epidemiol Biomarkers Prev 2007;16:70–6.
   PubMed Web of Science ®Google Scholar
• Norrish AE, McRae CU, Cohen RJ, Jackson RT. A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int 1999;84:311–5.
   PubMedGoogle Scholar
• Fromont G, Yacoub M, Valeri A, Mangin P, Vallacien G, Cancel-Tassin G, . Differential expression of genes related to androgen and estrogen metabolism in hereditary versus sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 2008;17:1505–9.
   PubMedGoogle Scholar
• Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun MJ, . Family history and risk of fatal prostate cancer. Epidemiology 1997;8:653–7.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA. Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 1997;15:1478–80.
   PubMedGoogle Scholar
• Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O. Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. Urology 2003;61:1193–7.
   PubMedGoogle Scholar
• Gronberg H, Damber L, Tavelin B, Damber JE. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998;82:564–7.
   PubMedGoogle Scholar
• Hanlon AL, Hanks GE. Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology 1998;52:735–8.
   PubMedGoogle Scholar
• Valeri A, Azzouzi R, Drelon E, Delannoy A, Mangin P, Fournier G, . Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 2000;45:66–71.
   PubMedGoogle Scholar
• Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA. Aggressiveness of familial prostate cancer. J Clin Oncol 2006;24:3445–50.
   PubMed Web of Science ®Google Scholar
• Roehl KA, Loeb S, Antenor JAV, Corbin N, Catalona WJ. Characteristics of patients with familial versus sporadic prostate cancer. J Urol 2006;176:2438–42.
   PubMed Web of Science ®Google Scholar
• Roupret M, Fromont G, Bitker M, Gattegno B, Vallancien G, Cussenot O. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology 2006;67:1028–32.
   PubMedGoogle Scholar
• Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol 2005;176:1118–21.
   Google Scholar
• Peters CA, Stock RG, Blacksburg SR, Stone NN. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:24–9.
   PubMedGoogle Scholar
• Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27–41.
   PubMed Web of Science ®Google Scholar
• Alers JC, Krijtenburg P-J, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WCJ, . Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies. Am J Pathol 2001;158:399–406.
   PubMedGoogle Scholar
• Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, . Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci 2004;101:811–6.
   PubMed Web of Science ®Google Scholar
• Nelson PS. Predicting prostate cancer behavior using transcript profiles. J Urol 2004;172:S28–S33.
   Google Scholar
• True L, Coleman I, Hawley S, Huang C-Y, Gifford D, Coleman R, . A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci 2006;103:10991–6.
   PubMed Web of Science ®Google Scholar
• Witte JS, Goddard KAB, Conti DV, Elston RC, Lin J, Suarez BK, . Genomwide scan for prostate cancer-aggressiveness loci. Am J Hum Genet 2000;67:92–9.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR. Inherited genotype and prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 2002;11:945–52.
   PubMedGoogle Scholar
• Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, . Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Onc 2008; 26:842–7.
   PubMedGoogle Scholar
• Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, . Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14:3312–8.
   PubMed Web of Science ®Google Scholar
• Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang Q-X, Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999;81:672–6.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Dahut WL, Figg WD. The genetics of castration-resistant prostate cancer: What can the germline tell us? Clin Cancer Res 2008;14:4691–3.
   PubMed Web of Science ®Google Scholar
• Yoon PW, Scheuner MT, Peterson-Oehlke KL, Gwinn M, Faucett A, Khoury MJ. Can family history be used as a tool for public health and preventive medicine? Genet Med 2002;4:304–10.
   PubMed Web of Science ®Google Scholar
• Toms JR. Cancer Stats monograph 2004. Cancer Research UK, 2004.
   Google Scholar
• U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;148:435–48.
   PubMedGoogle Scholar
• Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, . Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.o ng per milliliter. N Engl J Med 2004;350:2239–46.
   PubMed Web of Science ®Google Scholar
• Canby-Hagino E, Hernandez J, Brand TC, Troyer DA, Higgins B, Ankerst DP, . Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology 2007;70: 748–52.
   PubMedGoogle Scholar
• Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, . External validation of the prostate cancer prevention trial risk calculator in a screened population. Urology 2006;68:1152–5.
   PubMed Web of Science ®Google Scholar
• Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, . Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009;15:1787–93.
   PubMed Web of Science ®Google Scholar
• Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, . Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol 2009;182:101–5.
   PubMedGoogle Scholar
• Gallus S, Foschi R, Talamini R, Altieri A, Negri E, Franceschi S, . Risk factors for prostate cancer in men aged less than 60 years: A case-control study from Italy. Urology 2007;70:1121–6.
   PubMed Web of Science ®Google Scholar
• Drake BF, Lathan CS, Okechukwu CA, Bennett GG. Racial differences in prostate cancer screening by family history. Ann Epidemiol 2008;18:579–83.
   PubMedGoogle Scholar
• Andersson SO, Baron J, Wolk A, Lindgren C, Bergstrom R, Adami HO. Early life risk factors for prostate cancer: A population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1995;4:187–92.
   PubMedGoogle Scholar
• Hemminki K, Rawal R, Bermejo JL. Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer 2005;113:312–5.
   PubMedGoogle Scholar
• Bratt O, Gamo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, . Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 2010;102:1–8.
   Google Scholar
• Orom H, Kiviniemi MT, Underwood-III W, Ross L, Shavers VL. Perceived cancer risk: Why is it lower among nonwhites than whites? Cancer Epidemiol Biomarkers Prev 2010;19:746–54.
   PubMed Web of Science ®Google Scholar
• Wallner LP, Sarma AV, Lieber MM, St. Sauver JL, Jacobson DJ, McGree ME, . Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: The Olmsted County Study. Cancer Epidemiol Biomarkers Prev 2008;17:3588–92.
   PubMed Web of Science ®Google Scholar
• Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, . Estrogen-dependent signalling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100:815–25.
   PubMedGoogle Scholar
• Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, . CpG Island Hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 2007;179:529–35.
   Google Scholar
• Murphy TM, Perry AS, Lawler M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocrine-Related Cancer 2008;15:11–25.
   PubMed Web of Science ®Google Scholar